Precision BioSciences Announces $70M Stock Offering

Tip Ranks
2025.11.12 14:28
portai
I'm PortAI, I can summarize articles.

Precision BioSciences announced a $70 million stock offering, involving the sale of 10,815,000 shares and warrants, underwritten by Guggenheim Securities. The funds will support research, working capital, and corporate purposes, with the offering closing expected on November 12, 2025. Analysts rate DTIL stock as a Buy with a $60 price target, though Spark's AI Analyst gives it a Neutral score due to declining revenues and losses. Precision BioSciences focuses on gene editing technologies in the biotechnology sector, with a current market cap of $80.47 million.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Precision BioSciences ( (DTIL) ) just unveiled an announcement.

On November 10, 2025, Precision BioSciences, Inc. announced an underwriting agreement with Guggenheim Securities, LLC for the sale of 10,815,000 shares of common stock and accompanying warrants, expecting to raise approximately $70 million. The proceeds will be used for research and development, working capital, and other corporate purposes, with the offering’s closing anticipated on November 12, 2025, subject to customary conditions.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Spark’s Take on DTIL Stock

According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.

The overall stock score is primarily impacted by the company’s poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides a slightly more positive outlook with some bullish momentum, but valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on DTIL stock, click here.

More about Precision BioSciences

Precision BioSciences, Inc. operates in the biotechnology industry, focusing on the development and commercialization of gene editing technologies. The company primarily offers products and services related to the research and development of genetic therapies, aiming to address various genetic disorders and improve healthcare outcomes.

Average Trading Volume: 141,117

Technical Sentiment Signal: Hold

Current Market Cap: $80.47M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer